Biography
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials.
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Advanced Heart Failure and Transplant Cardiology (2014)
- Fellowship: Brigham and Women's Hospital Heart Transplant (2002) MA
- Fellowship: Brigham and Women's Hospital Cardiovascular Disease Fellowship (2001) MA
- Residency: Brigham and Women's Hospital Internal Medicine Residency (1998) MA
- Medical Education: Perelman School of Medicine University of Pennsylvania (1995) PA
Publications
-
-
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., … Temple, R. J. (2018). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. CIRCULATION, 137(9), 961–72. -
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland, F. R., Claggett, B., Burdmann, E. A., Chertow, G. M., Cooper, M. E., Eckardt, K.-U., … Pfeffer, M. A. (2018). Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. -
Response by Eberly et al to Letter Regarding Article, "Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center".
Eberly, L. A., Wispelwey, B., Richterman, A., Beckett, A. G., Cleveland Manchanda, E. C., Marsh, R. H., … Morse, M. (2020). Response by Eberly et al to Letter Regarding Article, "Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center". Circulation. Heart Failure, CIRCHEARTFAILURE120007193. -
Associations Between Depressive Symptoms and HFpEF-Related Outcomes.
Chandra, A., Alcala, M. A., Claggett, B., Desai, A. S., Fang, J. C., Heitner, J. F., … Lewis, E. F. (2020). Associations Between Depressive Symptoms and HFpEF-Related Outcomes. JACC. Heart Failure. -
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G., Lindenfeld, J. A., Mehran, R., … O'Connor, C. M. (2020). Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC). European Journal of Heart Failure. -
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
Wijkman, M. O., Claggett, B., Diaz, R., Gerstein, H. C., Kober, L., Lewis, E., … Pfeffer, M. A. (2020). Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovascular Diabetology, 19(1), 175. -
Cardiovascular Safety and Efficacy of Vadadust for the Treatment of Anemia in Non-Dialysis Dependent CKD: Design and Baseline Characteristics.
Chertow, G. M., Pergola, P. E., Agarwal, R., Block, G. A., Farag, Y. M., Jardine, A. G., … Eckardt, K.-U. (2020). Cardiovascular Safety and Efficacy of Vadadust for the Treatment of Anemia in Non-Dialysis Dependent CKD: Design and Baseline Characteristics. American Heart Journal. -
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.
Psotka, M. A., Abraham, W. T., Fiuzat, M., Filippatos, G., Lindenfeld, J. A., Ahmad, T., … O'Connor, C. M. (2020). Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. Journal of the American College of Cardiology, 76(20), 2368–78. -
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium.
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G., Lindenfeld, J. A., Mehran, R., … O'Connor, C. M. (2020). Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC. Heart Failure. -
A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD.
Toto, R., Petersen, J., Berns, J. S., Lewis, E. F., Tran, Q., & Weir, M. R. (2020). A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Journal of the American Society of Nephrology : JASN. -
IMPROVE-IT A Final Closure to Carcinogenicity of Ezetimibe?
Lewis, E. F., & Rhee, J.-W. (2020). IMPROVE-IT A Final Closure to Carcinogenicity of Ezetimibe? JACC: CARDIOONCOLOGY, 2(3), 397–99. -
Heart Failure Admission Service Triage (H-FAST) Study: Racialized Differences in Perceived Patient Self-Advocacy as a Driver of Admission Inequities.
Cleveland Manchanda, E. C., Marsh, R. H., Osuagwu, C., Decopain Michel, J., Dugas, J. N., Wilson, M., … Wispelwey, B. P. (2021). Heart Failure Admission Service Triage (H-FAST) Study: Racialized Differences in Perceived Patient Self-Advocacy as a Driver of Admission Inequities. Cureus, 13(2), e13381. -
Sex differences in congestive markers in patients hospitalized for acute heart failure.
Espersen, C., Campbell, R. T., Claggett, B., Lewis, E. F., Groarke, J. D., Docherty, K. F., … Platz, E. (2021). Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure. -
Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.
Jering, K. S., Claggett, B., Pfeffer, M. A., Granger, C., Kober, L., Lewis, E. F., … Braunwald, E. (2021). Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics. European Journal of Heart Failure. -
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow, G. M., Pergola, P. E., Farag, Y. M., Agarwal, R., Arnold, S., Bako, G., … Eckardt, K.-U. (2021). Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. The New England Journal of Medicine, 384(17), 1589–1600. -
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt, K.-U., Agarwal, R., Aswad, A., Awad, A., Block, G. A., Bacci, M. R., … Chertow, G. M. (2021). Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. The New England Journal of Medicine, 384(17), 1601–12. -
Disparity in the Setting of Incident Heart Failure Diagnosis.
Sandhu, A. T., Tisdale, R. L., Rodriguez, F., Stafford, R. S., Maron, D. J., Hernandez-Boussard, T., … Heidenreich, P. A. (2021). Disparity in the Setting of Incident Heart Failure Diagnosis. Circulation. Heart Failure, CIRCHEARTFAILURE121008538. -
Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial.
DeVore, A. D., Granger, B. B., Fonarow, G. C., Al-Khalidi, H. R., Albert, N. M., Lewis, E. F., … Hernandez, A. F. (2021). Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. JAMA, 326(4), 314–323. -
IMPROVE-IT: A Final Closure to Carcinogenicity of Ezetimibe?
Lewis, E. F., & Rhee, J.-W. W. (2020). IMPROVE-IT: A Final Closure to Carcinogenicity of Ezetimibe? JACC. CardioOncology, 2(3), 397–399. -
Association of Myocardial Blood Flow Reserve With Adverse Left Ventricular Remodeling in Patients With Aortic Stenosis: The Microvascular Disease in Aortic Stenosis (MIDAS) Study.
Zhou, W., Sun, Y.-P., Divakaran, S., Bajaj, N. S., Gupta, A., Chandra, A., … Di Carli, M. F. (2021). Association of Myocardial Blood Flow Reserve With Adverse Left Ventricular Remodeling in Patients With Aortic Stenosis: The Microvascular Disease in Aortic Stenosis (MIDAS) Study. JAMA Cardiology. -
A fourth pillar for all in the treatment of heart failure.
Lewis, E. F. (2021). A fourth pillar for all in the treatment of heart failure. European Heart Journal. -
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
Minamisawa, M., Claggett, B., Suzuki, K., Hegde, S. M., Shah, A. M., Desai, A. S., … Vardeny, O. (2021). Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. Heart Failure, CIRCHEARTFAILURE120008293. -
A-lines and B-lines in patients with acute heart failure.
Johannessen, Ø., Claggett, B., Lewis, E. F., Groarke, J. D., Swamy, V., Lindner, M., … Platz, E. (2021). A-lines and B-lines in patients with acute heart failure. European Heart Journal. Acute Cardiovascular Care, 10(8), 909–917. -
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Sandhu, A. T., Kohsaka, S., Turakhia, M. P., Lewis, E. F., & Heidenreich, P. A. (2021). Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. JAMA Cardiology. -
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Kober, L., Maggioni, A. P., … Braunwald, E. (2021). Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. The New England Journal of Medicine, 385(20), 1845–1855. -
Underrepresentation of Ethnic and Racial Minorities in Atrial Fibrillation Clinical Trials.
Nunes, J. C., Rice, E. N., Stafford, R. S., Lewis, E. F., & Wang, P. J. (2021). Underrepresentation of Ethnic and Racial Minorities in Atrial Fibrillation Clinical Trials. Circulation. Arrhythmia and Electrophysiology, CIRCEP121010452. -
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., … Braunwald, E. (2021). Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation.
Practice Locations
Heart Transplant Program Stanford, CA
Stanford, CAHeart Transplant Program
300 Pasteur Drive, 2nd Floor, Room A21
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Advanced Heart Failure Clinic at Stanford Stanford, CA
Stanford, CAAdvanced Heart Failure Clinic at Stanford
300 Pasteur Drive, 2nd Floor, Room A260
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Mechanical Circulatory Support Program Stanford, CA
Stanford, CAMechanical Circulatory Support Program
300 Pasteur Drive, 2nd Floor, Room A260
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(25 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records